Panmure Gordon reaffirmed their buy rating on shares of Vectura Group PLC (LON:VEC) in a research report report published on Thursday morning. The brokerage currently has a GBX 150 ($1.97) price target on the stock.
Several other brokerages also recently weighed in on VEC. Numis Securities Ltd reaffirmed a buy rating and issued a GBX 205 ($2.70) target price on shares of Vectura Group PLC in a research report on Thursday, September 7th. Peel Hunt reaffirmed a hold rating and issued a GBX 160 ($2.10) target price on shares of Vectura Group PLC in a research report on Tuesday, October 31st. J P Morgan Chase & Co decreased their target price on Vectura Group PLC from GBX 210 ($2.76) to GBX 180 ($2.37) and set an overweight rating for the company in a research report on Thursday, September 21st. Shore Capital reaffirmed a buy rating on shares of Vectura Group PLC in a research report on Wednesday, August 16th. Finally, Citigroup Inc. decreased their target price on Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a buy rating for the company in a research report on Monday, September 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of GBX 189.67 ($2.49).
Shares of Vectura Group PLC (LON VEC) traded down GBX 0.15 ($0.00) during midday trading on Thursday, hitting GBX 90.55 ($1.19). The stock had a trading volume of 2,724,522 shares, compared to its average volume of 1,560,000. Vectura Group PLC has a 52 week low of GBX 86.50 ($1.14) and a 52 week high of GBX 166.97 ($2.20).
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/11/vectura-group-plc-vec-receives-buy-rating-from-panmure-gordon.html.
In other news, insider Bruno Angelici acquired 70,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were purchased at an average price of GBX 99 ($1.30) per share, for a total transaction of £69,300 ($91,148.23). Also, insider Andrew Derodra acquired 82,000 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were purchased at an average price of GBX 90 ($1.18) per share, for a total transaction of £73,800 ($97,066.95). In the last quarter, insiders purchased 152,456 shares of company stock worth $14,354,880.
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.